Microbiome Characterization System for Allergy Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing human microbiomes and providing therapeutic measures for allergy-related conditions are limited due to inefficiencies in sample processing, genetic analysis, and data processing, leading to inconsistent and time-consuming diagnostic and treatment processes.
Innovation Solution
A method and system for generating microbiome datasets and processing supplementary data to characterize allergy-related conditions, using next-generation sequencing and machine learning algorithms to determine personalized therapies based on microbiome composition and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional sample processing and genetic analysis techniques are used, then the process is simpler and more established, but the characterization is inconsistent and time-consuming
Solution Approach 1:
The patent segments the microbiome characterization process into distinct computational stages: quality control filtering, taxonomy assignment, functional annotation, and statistical analysis. This segmentation allows each stage to be optimized independently, improving overall processing efficiency and consistency while maintaining accuracy.
Solution Approach 2:
The patent implements parameter changes by transitioning from conventional genetic analysis to next-generation sequencing technologies, and from manual analysis to automated machine learning algorithms. These parameter changes in processing methods dramatically reduce time while improving characterization precision through higher throughput and standardized protocols.
2Productivity
If conventional genetic analysis techniques are used, then the methodology is more established, but the data processing efficiency is low
Solution Approach 1:
The patent introduces computational intermediaries including bioinformatics pipelines, machine learning models, and data processing software that mediate between raw sequencing data and clinical interpretations. These intermediaries automate complex data processing tasks, dramatically improving productivity while managing system complexity through standardized computational workflows.
Solution Approach 2:
The patent replaces manual and mechanical analysis methods with automated computational systems. Machine learning algorithms and bioinformatics tools substitute for conventional labor-intensive genetic analysis, enabling high-throughput processing of microbiome data with improved efficiency and reduced human error.
3Reliability
If personalized therapies are developed based on microbiome composition, then treatment effectiveness is improved, but the resource requirements increase
Solution Approach 1:
The patent performs preliminary computational analysis of microbiome composition and function before therapy development. By pre-characterizing the microbiome state and identifying relevant taxa and functions, the system enables targeted therapy development that improves effectiveness while optimizing resource allocation through data-driven decision-making.
Solution Approach 2:
The patent transforms microbiome composition data into actionable therapeutic parameters through computational analysis. By converting complex microbiome profiles into standardized characterization metrics and therapy recommendations, the system improves treatment effectiveness while managing resource requirements through efficient data utilization.
Data Source
AI summary
Embodiments of a method and/or system for characterizing an allergy-related condition for a user can include one or more of: generating a microbiome dataset for each of an aggregate set of biological samples associated with a population of subjects, based on sample processing of the biological samples; processing a supplementary dataset associated with one or more allergy-related conditions for the set of users; and performing an allergy-related characterization process for the one or more allergy-related conditions, based on the supplementary dataset and/or microbiome features extracted from the microbiome dataset.